Neurorehab
  • 1. Varga F, Málly J, Fisher E. Effect of insulin on the biliary excretion of some organic anions in rats. Arch Toxicol 1980, Suppl, 4, 391-93.
  • 2. Málly J, Horváth M, Guseo A. Motoros teljesitmények vizsgálata ambulans körülmények között Parkinson szindrómában. Ideggyógy Szle 1986, 39, 265-68.
  • 3. Málly J, Guseo A. A Jumex monoterápias hatása Parkinson szindrómában. Idegyógy Szle 1986, 39, 90-95.
  • 4. Guseo A, Málly J. Terápiás kisérletek sklerosis multiplexes betegek posturalis (akciós) tremorának kezelésére. Ideggyógy Szle 1986, 39, 258-264.
  • 5. Málly J. Evidence of adenosine receptors in essential tremor provided by the treatment of low dose theophylline therapy.: New Trends in Clinical Neuropharmacology ed by D. Bartko, John Libbey and Co.Ltd. 324-329 1988.
  • 6. Málly J. Effect of low dose theophylline therapy on essential tremor. New Trends in Clinical Neuropharmacology 1988, 1, 51-55.
  • 7. Málly J. Aminophyline and essential tremor. Lancet, 1999, 2, 278-279.
  • 8. Málly J. A pentoxifillin (Trental 400) hatásai és klinikai alkalmazása. Medicus Universalis 1990, Suppl, XXIII-2 11-15.
  • 9. Málly J, Connick JH and Stone TW. Theophylline down-regulates adenosine receptor function. Brain Res 1990, 509, 141-144. 2.719
  • 10. Málly J, Connick JH and Stone TW. Chronic benzodiazepine treatment and cortical responsees to adenosine and GABA. Brain Res 1990, 530, 353-357. 2.719
  • 11. Málly J, Connick JH and Stone TW. Changes in neurotransmitter sensitivity in the mouse neocortical slice following propranolol and theophylline administration. Br J Pharmacol 1991, 102, 711-717 . 4.786
  • 12. Málly J, Stone TW. The effect of theophylline on essential tremor: the role of GABA. Pharmacol Biochem Behav 1991, 39, 345-351. 1.679
  • 13. Málly J. Some new aspects of the effect of (-)deprenyl in Parkinson s disease in a retrospective study. J Neurol Transm (P-D Sect) 1982, 4, 155-164. 1.574
  • 14. Málly J, Keszei Cs, Cserép Gy. Theophylline concentration in serum, saliva and cerebrospinal fluid in patients with essential tremor. Therapeutic Drug Monitoring 1992, 14, 135-137. 1.308
  • 15. Málly J. Teofillin hatása essentialis tremorban. Gyógyszereink 1991, 41, 221-223.
  • 16. Málly J. (-) depenyl (Jumex) terápia Parkinson szindrómában. Lege Artis Medicinae LAM 1991, 1(18) 1328-1333.
  • 17. Málly J. A teofillin és propranolol összehasonlitó vizsgálata essentialis tremorban O H 1992, 133, 981-983.
  • 18. Málly J. The effect of selegiline monotherapy in Parkinson s disease. Proceedings of Synposium in Parkinson s disease Recent Advances in Therapy ed MCMaheshwari New Delhi 16-28 1991.
  • 19. Bain PD, Málly J, Gresty M, Findley LJ. Assessing the impact of essential tremor on upper limb function. J Neurol 1993, 241, 54-61.
  • 20. Málly J, Baranyi M. Change in the concentrations of amino acids in cisternal CSF of patients with essential tremor. J Neurol Neurosurg Psychiatry 1994, 57, 1012-13.
  • 21. Málly J, Stone TW. The effect of theophylline on parkinsonian symptoms. J Pharm Pharmacol 1994, 46, 515-517.
  • 22. Málly J, Stone TW. Efficacy of an adenosine antagonist, theophylline in essential tremor, comparison with placebo and propranolol. J Neurol Sci 1995, 132, 129-132.
  • 23. Málly J. A leggyakoribb tremor fajták differenciáldiagnosztikája. OH 1995, 136, 2211-2216. Az „Orvosi Hetilap Markusovszky Lajos Díj”-jával jutalmazva.
  • 24. Málly J, Kovács AB, Stone TW. Delayed development of symptomatic improvement by (-) deprenyl in Parkinson s disease J Neurol Sci 1995, 134, 143-145.
  • 25. Málly J, Baranyi M, Vizi ES. Change in the concentrations of amino acids in CSF and Serum of patients with essential tremor. J Neural Transm 1996, 103, 555-560.
  • 26. Málly J, Stone TW. Potential role of adenosine antagonist therapy in pathological tremor disorders. Pharmacol Ther 1996, 72, 243-250.
  • 27. Málly J, Szalai G, Stone TW. Change in the concentration of amino acids in serum and CSF of patients with Parkinson’s disease. J Neurol Sci 1997, 151,159-162.
  • 28. A tremor terápiája. Human farmakológia. Dr. Vizi E. Szilveszter és társszerzői. 1997. Medicina könyvkiadó.
  • 29. Málly J, Stone TW. Lamotrigine in essential tremor. Pharmaceutical Sciences 1997, 3, 207-209.
  • 30. Málly J, Szalai G, Bartók T, Stone TW. Serum amino acid levels as a possible diagnostic differentiation between essential tremor and Parkinsonian tremor. Med Sci Res 1997, 25, 519-520.
  • 31. Málly J. Aminophylline and essential tremor. Br J Clin Pharmacol 1997, 44, 412.
  • 32. Eder U, Leitner B, Kirchmair R, Pohl P, Jobst KA, Smith AD, Málly J, Benczer A, Riederer P, Reichmann H, Saria A, Winkler H. Levels and proteolitic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological disease. J Neural Transm 1998, 105, 39-51.
  • 33. Málly J, Stone TW. Potential of adenosine A2A receptor antagonists in the treatment of movement disorders CNS Drugs 1998, 10 (5), 311-320.
  • 34. Málly J, Stone TW. Lasting improvement in parkinsonian symptoms after repetitive transcranial magnetic stimulation. Med Sci Res 1998, 26, 521-523.
  • 35. Málly J. A kézremegés terápiája. Kórház 1999, 3, 2-4.
  • 36. Málly J, Stone TW. Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation. J Neurol Sci 1999, 162, 179-184.
  • 37. Málly J, Stone TW. Therapeutic and „dose-dependent” effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson s disease. J Neurosci Res 1999, 57, 935-940.
  • 38. Málly J. Kéztremor. Praxis 2000, 9, 7-14.
  • 39. Málly J. A változó elektromágneses térrel kiváltott mikroelektroshock terápiás hatása Parkinson-kórban. Kórház 2000 6/7 25-29.
  • 40. Málly J. Transcranialis mágnes stimuláció (TMS) a diagnosztikában, az agy fiziológiai kutatásában és a neuropsychiatriai betegségek kezelésében. 2004. Pécs egyetemi jegyzet
  • 41. Málly J, Farkas R, Tóthfalusi L, Stone TW. Long term follow-up study with repetitive trascranial magnetic stimulation (rTMS) in Parkinson’s disease. Brain Res Bull 2004, 64, 259-263.
  • 42. Málly J, Stone W. New advances in the rehabilitation of CNS diseases applying rTMS. Exp. Rev. Neurotherapeutics 2007, 7, 165-177.
  • 43. Málly J, Dinya E. Recovery of motor disability and spasticity in post-stroke after repetitive transcranial magnetic stimulation (rTMS). Brain Res. Bull. 2008, 76, 388-395.
  • 44. The Repetitive Transcranial Magnetic Stimulation in the Treatment and Rehabilitation of Central Nervous Diseases Ed. By J. Málly Publisher: Eurobridge Co. Budapest 2009.
  • 45. Málly J. Non-invasive brain stimulation (rTMS+tDCS) in patients with aphasia: Mode of action at the cellular level. Brain Res Bull 2013, 98, 30-35.
  • 46. Voitenkov V, Málly J, Skripcenko HB, Klimkin AAV. Transcranial magnetic stimulation as a diagnostic and therapeutic tool. Nevrology 2015, 5, 3-13.
  • 47. Málly J, Geisz N, Dinya E. Follow-up study: The influence of rTMS with high and low frequency stimulation on motor and executive function in Parkinson’s disease.Brain Res Bull 2017, 135, 98-10
  • 48. Sinkó G, Hoffer K, Hajas Á, Harangi M, Varga VE, Balogh I, Málly J. Cerebrotendinosus xanthomatosis-kezelhető neurogenetikai betegség.Ed. by Garzuly F, Tóth Cs., Kálmán B. Ritka betegségek diagnosztika és terápia. Orioldes Társai Kft.2017
  • 49. Málly J, Stone TW, Sinkó G, Geisz N, Dinya E. Long term, follow-up study of non-invasive brain stimulation (NBS) (rTMS and tDCS) in Parkinson’s disease (PD).Strong age-dependency in the effect of NBS. Brain Res Bull 2018, 142, 78-87.
  • 50. Halmi Zs, Dinya E, Málly J. Destroyed non-dopaminergic pathways in the early stageof Parkinson’s disease assessed by posturography. Brain Res Bull 2019, 152, 45-51.
  • 51. Halmi Zs, Stone TW, Dinya E, Málly J. Postural instability years after stroke. J Stroke Cerebrovasc Dis 2020, 29, 1-14.
  • 52. Szögedi D, TW Stone, E Dinya, J Málly. Dual-task performance testing as an indicatorof cognitive deterioration in Parkinson’s Disease: A pilot study. J PsychiatryPsychiatric Dis 2023, 7, 104-117.
  • 53. Tompa M, Sinko G, Málly J, Karteszi J, Kálmán B. Using whole exome sequencing toidentify genetic cause of neurodevelopmental disorders in a cohort of 11 patients: Asingle center experience. Int J Mol Sci 2025, 26, 10176
  • 54. Málly J, Karácsony O, Kálmán B, Stone TW. The contribution of paresis, age, and theeffect of short training on cognitive-motor dual-task interference after stroke: A pilotstudy. Life, 2025, 15, 1881-1894.